Common use of Tests and Preclinical and Clinical Trials Clause in Contracts

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, all Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; except to the extent disclosed in the Registration Statement and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes materially call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials.

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, to accepted professional scientific standards and all Authorizations and Applicable Regulatory Laws, including, as applicable, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules and regulations thereunder; the descriptions of the jurisdiction results of such studies, tests and trials contained in which the Public Disclosure Record are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such trials studies, tests and studies are being conductedtrials; except to the extent disclosed in the Registration Statement and Public Disclosure Record, or would not, singly or in the Prospectusaggregate, result in a Material Adverse Effect, the Company is not aware of any studies, tests or trials, the results of which the Company believes materially reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus Public Disclosure Record when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or the ProspectusPublic Disclosure Record, the Company has not received any written notices or correspondence from the FDA or any governmental entity Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials.

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s 's knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, to accepted professional scientific standards and all Applicable Lawsauthorizations and applicable regulatory laws, including, as applicable, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules and regulations thereunder; the descriptions of the jurisdiction results of such studies, tests and trials contained in which the Registration and the Prospectus Supplement are, to the Company's knowledge, accurate and complete in all material respects and fairly present the data derived from such trials studies, tests and studies are being conductedtrials; except to the extent disclosed in the Registration Statement and the ProspectusProspectus Supplement, or would not, singly or in the aggregate, result in a Material Adverse Effect, the Company is not aware of any studies, tests or trials, the results of which the Company believes materially reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus Supplement when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or and the ProspectusProspectus Supplement, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials.

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, or on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current Good Clinical Practices and Good Laboratory Practices and any applicable rules rules, regulations and regulations policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained or incorporated by reference in the Registration Statement and the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes materially reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, to accepted professional scientific standards and all Authorizations and Applicable Laws, including, as applicable, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules and regulations (collectively, “FFDCA”); the descriptions of the jurisdiction results of such studies, tests and trials contained in which the Prospectuses are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such trials studies, tests and studies are being conductedtrials; except to the extent disclosed in the Registration Statement and Prospectuses, or would not, singly or in the Prospectusaggregate, result in a Material Adverse Effect, the Company is not aware of any studies, tests or trials, the results of which the Company believes materially reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus Prospectuses when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or the ProspectusProspectuses, the Company has not received any written notices or correspondence from the FDA or any governmental entity Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Tests and Preclinical and Clinical Trials. The To the knowledge of the Company, the studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, or on behalf of the Company or its Subsidiaries, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant toto accepted professional scientific standards and all permits and licenses and applicable Laws including, where as applicable, all Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder and any applicable rules and regulations thereunder. The descriptions of the jurisdiction results of such studies, tests and trials contained in which the Company SEC Documents are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such trials studies, tests and studies are being conducted; trials, except to the extent disclosed in the Registration Statement and Company SEC Documents. Except to the Prospectusextent disclosed in the Company SEC Documents, (i) the Company is not aware of any studies, tests or trials, the results of which the Company believes materially reasonably call into question the study, test, or trial results described or referred to in the Registration Statement and the Prospectus Company SEC Documents when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement or the Prospectus, and (ii) the Company has and its Subsidiaries have not received any written notices or correspondence from the FDA United States Food and Drug Administration, any regulatory agencies or any governmental entity other Governmental Authorities requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the CompanyCompany or its Subsidiaries, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials.